--- title: "Eloralintide: Amylin and the Phase 2 Weight-Loss Results" url: https://www.bodyhackguide.co/blog/eloralintide-phase-2-results description: "Eloralintide is an amylin agonist, not a GLP-1 drug. Examine its 263-person, 48-week phase 2 trial, the 20.1% headline and evidence gaps." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: Eloralintide: Amylin and the Phase 2 Weight-Loss Results (https://www.bodyhackguide.co/assets/eloralintide-research-DOSdZk0X.jpg) Research 4 min read Oct 21, 2026 Fact-checked (https://www.bodyhackguide.co/editorial-standards) # Eloralintide: Amylin and the Phase 2 Weight-Loss Results Eloralintide is an amylin agonist, not a GLP-1 drug. Examine its 263-person, 48-week phase 2 trial, the 20.1% headline and evidence gaps. B BodyHackGuide Evidence notes from published research and trial registries. Educational information, not medical or dental advice. Key Takeaway **Eloralintide is an investigational selective amylin receptor agonist, not a GLP-1 agonist.** Its phase 2 trial reported 9.5% to 20.1% mean weight loss at 48 weeks across treatment arms, versus 0.4% with placebo, under an efficacy estimand. The study did not demonstrate superiority to GLP-1 medicines. Evidence checked October 21, 2026. “Elorinatide” is a misspelling sometimes used for eloralintide. We use the trial's actual name here. This is research reporting, not a treatment or dosing guide. ## What makes eloralintide different? Eloralintide, also called LY3841136, targets amylin receptors. UBT251 and retatrutide instead target GLP-1, GIP and glucagon receptors. That distinction is useful when following trial programs; it does not tell us which medicine would work best for a particular person. We link mechanisms to the evidence rather than assuming a new pathway means fewer adverse effects. The published Lancet phase 2 trial (https://pubmed.ncbi.nlm.nih.gov/41207310/) is the primary source for this article. ## What did the phase 2 trial measure? The randomized, double-blind, placebo-controlled trial enrolled **263 adults at 46 US centers**. Eligibility included ages 18–75 and obesity, or overweight with at least one weight-related comorbidity. Participants did not have type 2 diabetes. Its primary endpoint was percentage body-weight change at week 48. Our table keeps the headline attached to that population and analysis. | Question | Evidence from this trial | Limit | | --- | --- | --- | | How many participants? | 263 adults | Too small to settle rare adverse effects | | How long? | 48 weeks | Does not establish long-term maintenance after stopping | | Mean loss across eloralintide arms? | 9.5%–20.1% under the efficacy estimand | The highest arm is not the whole trial's average | | Placebo mean loss? | 0.4% | A within-trial comparator | | Active comparator? | None | No direct ranking against semaglutide, tirzepatide or retatrutide | Sources: Lancet paper (https://doi.org/10.1016/S0140-6736(25)02155-5) and Lilly's November 6, 2025 results announcement (https://investor.lilly.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated). ## What does efficacy estimand mean? An estimand defines the treatment effect researchers are trying to estimate, including how they handle events such as stopping treatment or starting other therapies. An efficacy estimand asks about an effect under specified adherence assumptions. It is not simply the observed average for every person who started, regardless of what happened next. For that reason, we label 20.1% with its analysis rather than implying everyone entering treatment should expect it. The retatrutide evidence card (https://www.bodyhackguide.co/guides/retatrutide-phase-3-card) shows why different ways of counting participants can yield different results within a single trial. ## Eloralintide versus UBT251: don't rank these percentages These are separate studies. Our comparison is deliberately about design, not a winner. | Feature | Eloralintide phase 2 | UBT251 phase 2 | | --- | --- | --- | | Main receptor mechanism | Selective amylin agonism | GLP-1/GIP/glucagon agonism | | Population | 263 US adults without type 2 diabetes | 205 Chinese adults without type 2 diabetes | | Primary endpoint timing | 48 weeks | 24 weeks | | Greatest reported mean loss | 20.1%, efficacy estimand | 19.7%, published phase 2 estimate | | Placebo mean loss | 0.4% | 2.0% | | Head-to-head comparison between them | No | No | Sources: eloralintide paper (https://pubmed.ncbi.nlm.nih.gov/41207310/) and UBT251 paper (https://doi.org/10.1016/j.cmet.2026.09.021). Different duration, population and analysis make a simple percentage ranking misleading. ## Safety and development: what remains unresolved? A placebo-controlled amylin study cannot establish “fewer side effects than GLP-1 drugs.” That would require a suitable direct comparison, including adverse-event severity, discontinuations and exposure time. We do not substitute a mechanism story for those data. The phase 2 registry (https://clinicaltrials.gov/study/NCT06230523) records actual enrollment of 263 and study completion in August 2025. Lilly's 2025 announcement described future development plans; those plans are not proof of later trial completion or regulatory approval. This article reports the verified phase 2 evidence and does not present a company roadmap as a current approval record. Durability after stopping, broader populations and longer-term safety remain separate evidence questions. For background on the compound, see our eloralintide reference page (https://www.bodyhackguide.co/compound/eloralintide). ## Sources and related research - PubMed record and abstract: Billings et al.: https://pubmed.ncbi.nlm.nih.gov/41207310/ - Lancet phase 2 paper (https://doi.org/10.1016/S0140-6736(25)02155-5) - Lilly results announcement, November 6, 2025: https://investor.lilly.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated - NCT06230523 registry: https://clinicaltrials.gov/study/NCT06230523 - UBT251 trial results and their limits: https://www.bodyhackguide.co/blog/ubt251-phase-2-results ## Frequently asked No. It is a selective amylin receptor agonist. Its mechanism differs from GLP-1 agonists and triple GLP-1/GIP/glucagon agonists. ## Related Articles Research ### UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim Read https://www.bodyhackguide.co/blog/ubt251-phase-2-results Research ### P11-4 and Curodont: What Enamel-Repair Trials Show Read https://www.bodyhackguide.co/blog/p11-4-enamel-repair-evidence ## New guides, by email New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime. No spam. Unsubscribe anytime. Share this article: 𝕏 / Twitter (https://twitter.com/intent/tweet?text=Eloralintide%3A%20Amylin%20and%20the%20Phase%202%20Weight-Loss%20Results&url=https%3A%2F%2Fwww.bodyhackguide.co%2Fblog%2Feloralintide-phase-2-results) B BodyHackGuide (https://www.bodyhackguide.co/about)Research editorial Join r/BodyHackGuide on Reddit: https://reddit.com/r/bodyhackguide Join Discord: https://discord.gg/Mhq5UdRYBA | About the author: https://www.bodyhackguide.co/about Back to all articles: https://www.bodyhackguide.co/blog Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://www.bodyhackguide.co/blog" }, { "@type": "ListItem", "position": 3, "name": "Eloralintide: Amylin and the Phase 2 Weight-Loss Results" } ] }, { "@context": "https://schema.org", "@type": "BlogPosting", "headline": "Eloralintide: Amylin and the Phase 2 Weight-Loss Results", "description": "Eloralintide is an amylin agonist, not a GLP-1 drug. Examine its 263-person, 48-week phase 2 trial, the 20.1% headline and evidence gaps.", "image": "/assets/eloralintide-research-DOSdZk0X.jpg", "datePublished": "2026-10-21T05:52:00Z", "dateModified": "2026-10-21T05:52:00Z", "author": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co/about" }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } }, "mainEntityOfPage": "https://www.bodyhackguide.co/blog/eloralintide-phase-2-results", "wordCount": 782, "timeRequired": "PT4M", "articleSection": "Research", "inLanguage": "en-US", "isAccessibleForFree": true, "speakable": { "@type": "SpeakableSpecification", "cssSelector": [ "h1", ".blog-tldr", "article p:first-of-type" ] } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is eloralintide a GLP-1 drug?", "acceptedAnswer": { "@type": "Answer", "text": "No. It is a selective amylin receptor agonist. Its mechanism differs from GLP-1 agonists and triple GLP-1/GIP/glucagon agonists." } }, { "@type": "Question", "name": "Does eloralintide cause 20.1% weight loss for everyone?", "acceptedAnswer": { "@type": "Answer", "text": "No. That is the highest mean loss reported across the trial's treatment arms under an efficacy estimand at 48 weeks. Individual outcomes vary, and that analysis is not an unconditional real-world forecast." } }, { "@type": "Question", "name": "Is eloralintide better than retatrutide?", "acceptedAnswer": { "@type": "Answer", "text": "The cited phase 2 trial cannot answer that. It compared eloralintide with placebo, not retatrutide. Different studies cannot establish head-to-head superiority." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```